Population
161 US vascular neurologists affiliated with a university (81% male) out of 400 surveyed.
Design
Cross-sectional
Authors
Loading...
Widespread off-label extended-window reperfusion coexists with reported equipoise; leaves open barriers to placebo-controlled trial enrollment.
Despite widespread off-label use of reperfusion therapies beyond 3 hours for acute ischemic stroke, vascular neurologists report high willingness to enroll patients in placebo-controlled trials, highlighting a paradox that may impair trial enrollment.
Khoury et al. (2010) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: